Clinical Study of CN128 in Thalassemia Patients

Key facts

Sponsor

Hangzhou Zede Pharma-Tech Co., Ltd.

Principal Investigator

Jianzhong Shentu

Single center

Intervention

CN128(drug)

Enrollment

32 enrolled

Eligibility

16 years · All sexes

Timeline

2018 – 2019

Study locations (1)

• The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07087262
  A Phase I Study of SNH-119014 in Healthy Volunteers
  ScinnoHub Pharmaceutical Co., Ltd.
• RECRUITINGNANCT06886477
  Sickle Cell, Pain and Mediterranean Diet
  University of Illinois at Chicago
• RECRUITINGPHASE1, PHASE2NCT06144749
  A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
  Hillhurst Biopharmaceuticals, Inc.
• RECRUITINGNANCT07064941
  Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
  University of California, San Francisco
• ACTIVE NOT RECRUITINGNANCT06800495
  Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Screening
  Universiti Teknologi Mara
• ENROLLING BY INVITATIONNCT07003256
  Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
  Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06481306
  A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  Bristol-Myers Squibb
• RECRUITINGNANCT06031714
  Fetal Cell Receptors Repertoire
  Assistance Publique - Hôpitaux de Paris

See all trials for Genetic hemoglobinopathy →